AP3437A - Methods of using and compositions comprising pde4 modulations for treatment, prevention and management of tuberculosis - Google Patents
Methods of using and compositions comprising pde4 modulations for treatment, prevention and management of tuberculosisInfo
- Publication number
- AP3437A AP3437A AP2011005849A AP2011005849A AP3437A AP 3437 A AP3437 A AP 3437A AP 2011005849 A AP2011005849 A AP 2011005849A AP 2011005849 A AP2011005849 A AP 2011005849A AP 3437 A AP3437 A AP 3437A
- Authority
- AP
- ARIPO
- Prior art keywords
- pde4
- modulations
- tuberculosis
- prevention
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15146709P | 2009-02-10 | 2009-02-10 | |
PCT/US2010/023533 WO2010093588A1 (en) | 2009-02-10 | 2010-02-09 | Methods of using and compositions comprising pde4 modulators for treatment, prevention and management of tuberculosis |
Publications (2)
Publication Number | Publication Date |
---|---|
AP2011005849A0 AP2011005849A0 (en) | 2011-08-31 |
AP3437A true AP3437A (en) | 2015-10-31 |
Family
ID=42077260
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AP2011005849A AP3437A (en) | 2009-02-10 | 2010-02-09 | Methods of using and compositions comprising pde4 modulations for treatment, prevention and management of tuberculosis |
Country Status (23)
Country | Link |
---|---|
US (1) | US20120149716A1 (xx) |
EP (2) | EP2395995A1 (xx) |
JP (2) | JP2012517441A (xx) |
KR (1) | KR20110116049A (xx) |
CN (1) | CN102387798A (xx) |
AP (1) | AP3437A (xx) |
AU (1) | AU2010213936B2 (xx) |
BR (1) | BRPI1007500A2 (xx) |
CA (1) | CA2750123A1 (xx) |
CO (1) | CO6410289A2 (xx) |
CR (1) | CR20110411A (xx) |
EA (1) | EA201171035A1 (xx) |
EC (1) | ECSP11011295A (xx) |
HK (1) | HK1205681A1 (xx) |
IL (1) | IL214176A (xx) |
MX (1) | MX2011008132A (xx) |
MY (1) | MY160002A (xx) |
NI (1) | NI201100154A (xx) |
NZ (1) | NZ594193A (xx) |
PE (2) | PE20120580A1 (xx) |
SG (2) | SG10201402158VA (xx) |
UA (1) | UA103791C2 (xx) |
WO (1) | WO2010093588A1 (xx) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012083017A2 (en) | 2010-12-16 | 2012-06-21 | Celgene Corporation | Controlled release oral dosage forms of poorly soluble drugs and uses thereof |
SG11201400632YA (en) | 2011-09-14 | 2014-04-28 | Celgene Corp | Formulations of cyclopropanecarboxylic acid {2-(1s)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1h-isoindol-4-yl}-amidecelgene corporation state of incorporation:delaware |
EP3756650A1 (en) | 2011-12-27 | 2020-12-30 | Amgen (Europe) GmbH | Formulations of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetyl aminoisoindoline-1,3-dione |
WO2013119607A2 (en) * | 2012-02-08 | 2013-08-15 | Celgene Corporation | Modified release formulations of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetyl aminoisoindoline-1,3-dione |
EP2764866A1 (en) | 2013-02-07 | 2014-08-13 | IP Gesellschaft für Management mbH | Inhibitors of nedd8-activating enzyme |
WO2017030892A1 (en) | 2015-08-14 | 2017-02-23 | Reaction Biology Corp. | Histone deacetylase inhibitors and methods for use thereof |
WO2017070291A1 (en) * | 2015-10-21 | 2017-04-27 | Celgene Corporation | Pde4 modulators for treating and preventing immune reconstitution inflammatory syndrome (iris) |
DE102018201827A1 (de) * | 2017-02-28 | 2018-08-30 | Aktiebolaget Skf | Wälzlager |
CN112220785B (zh) * | 2020-09-22 | 2021-12-31 | 北京鑫开元医药科技有限公司 | 一种pde4抑制剂药物组合物及其制备方法与用途 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001045702A1 (en) * | 1999-12-21 | 2001-06-28 | Celgene Corporation | SUBSTITUTED ACYLHYDROXAMIC ACIDS AND METHOD OF REDUCING TNFα LEVELS |
WO2003080049A1 (en) * | 2002-03-20 | 2003-10-02 | Celgene Corporation | (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
WO2004043378A2 (en) * | 2002-11-06 | 2004-05-27 | Celgene Corporation | Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases |
WO2007108750A1 (en) * | 2006-03-22 | 2007-09-27 | Astrazeneca Ab | Pyridopyrimidine derivatives and their use as pde4 inhibitors |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
US5605914A (en) | 1993-07-02 | 1997-02-25 | Celgene Corporation | Imides |
US5698579A (en) | 1993-07-02 | 1997-12-16 | Celgene Corporation | Cyclic amides |
US5463063A (en) | 1993-07-02 | 1995-10-31 | Celgene Corporation | Ring closure of N-phthaloylglutamines |
IT1276040B1 (it) * | 1993-07-27 | 1997-10-24 | Angelini Francesco Ist Ricerca | Uso della benzidamina nel trattamento di stati patologici causati dal tnf |
WO1995024398A1 (en) * | 1994-03-09 | 1995-09-14 | Pfizer Inc. | Isoxazoline compounds as inhibitors of tnf release |
US5610198A (en) * | 1994-03-18 | 1997-03-11 | The United States Of America As Represented By The Department Of Health And Human Services | Anti-mycobacterial compositions and their use for the treatment of tuberculosis and related diseases |
IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
US6429221B1 (en) | 1994-12-30 | 2002-08-06 | Celgene Corporation | Substituted imides |
US5703098A (en) | 1994-12-30 | 1997-12-30 | Celgene Corporation | Immunotherapeutic imides/amides |
US5801195A (en) | 1994-12-30 | 1998-09-01 | Celgene Corporation | Immunotherapeutic aryl amides |
US6518281B2 (en) | 1995-08-29 | 2003-02-11 | Celgene Corporation | Immunotherapeutic agents |
US5728844A (en) | 1995-08-29 | 1998-03-17 | Celgene Corporation | Immunotherapeutic agents |
US5728845A (en) | 1995-08-29 | 1998-03-17 | Celgene Corporation | Immunotherapeutic nitriles |
US5658940A (en) | 1995-10-06 | 1997-08-19 | Celgene Corporation | Succinimide and maleimide cytokine inhibitors |
DE69739181D1 (de) | 1996-08-12 | 2009-02-05 | Celgene Corp | Neue immunotherapeutische Mittel und deren Verwendung in der Reduzierung von Cytokinenspiegel |
DE69813876T2 (de) | 1997-07-31 | 2004-01-29 | Celgene Corp | Susstituierte alkanhydroxamisaeure und verfahren zur verminderung des tnf-alphaspiegels |
US6020358A (en) | 1998-10-30 | 2000-02-01 | Celgene Corporation | Substituted phenethylsulfones and method of reducing TNFα levels |
US6667316B1 (en) | 1999-11-12 | 2003-12-23 | Celgene Corporation | Pharmaceutically active isoindoline derivatives |
US6326388B1 (en) | 1999-12-21 | 2001-12-04 | Celgene Corporation | Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha level |
US8030343B2 (en) * | 2000-06-08 | 2011-10-04 | Celgene Corporation | Pharmaceutically active isoindoline derivatives |
PL355844A1 (en) * | 2000-08-09 | 2004-05-31 | Panacea Biotec Limited | Novel pharmaceutical compositions of anti-tubrcular drugs and process for their preparation |
WO2003080048A1 (en) | 2002-03-20 | 2003-10-02 | Celgene Corporation | (-)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
BR0316256A (pt) | 2002-11-18 | 2005-10-04 | Celgene Corp | Métodos de inibir a produção de tnf-alfa e a atividade de pde4, de tratar ou prevenir uma doença ou um distúrbio, de controlar os nìveis de camp em uma célula e de produzir um composto, composição farmacêutica e composto |
CN1802353A (zh) | 2002-12-30 | 2006-07-12 | 细胞基因公司 | 氟烷氧基取代的1,3-二氢-异吲哚化合物及其药物用途 |
CN101053558A (zh) | 2003-03-05 | 2007-10-17 | 细胞基因公司 | 二苯基乙烯化合物及其用途 |
DE602004032522D1 (de) | 2003-03-12 | 2011-06-16 | Celgene Corp | Mit n-alkylhydroxamsäuren substituierte isoindolylverbindungen und deren pharmazeutische verwendung |
US7034052B2 (en) | 2003-03-12 | 2006-04-25 | Celgene Corporation | 7-Amido-isoindolyl compounds and their pharmaceutical uses |
US7244259B2 (en) | 2003-10-31 | 2007-07-17 | Ethicon, Inc. | Guide for surgical device for the treatment of urinary incontinence |
US7405237B2 (en) | 2004-07-28 | 2008-07-29 | Celgene Corporation | Isoindoline compounds and methods of their use |
US7244759B2 (en) | 2004-07-28 | 2007-07-17 | Celgene Corporation | Isoindoline compounds and methods of making and using the same |
WO2006065814A1 (en) * | 2004-12-13 | 2006-06-22 | Celgene Corporation | Compositions comprising pde4 modulators and their use for the treatment or prevention of airway inflammation |
-
2010
- 2010-02-09 AU AU2010213936A patent/AU2010213936B2/en not_active Ceased
- 2010-02-09 EP EP10704460A patent/EP2395995A1/en not_active Withdrawn
- 2010-02-09 MY MYPI2011003673A patent/MY160002A/en unknown
- 2010-02-09 SG SG10201402158VA patent/SG10201402158VA/en unknown
- 2010-02-09 MX MX2011008132A patent/MX2011008132A/es active IP Right Grant
- 2010-02-09 EA EA201171035A patent/EA201171035A1/ru unknown
- 2010-02-09 JP JP2011549315A patent/JP2012517441A/ja active Pending
- 2010-02-09 KR KR1020117021146A patent/KR20110116049A/ko not_active Application Discontinuation
- 2010-02-09 WO PCT/US2010/023533 patent/WO2010093588A1/en active Application Filing
- 2010-02-09 CN CN2010800159215A patent/CN102387798A/zh active Pending
- 2010-02-09 SG SG2011054129A patent/SG173149A1/en unknown
- 2010-02-09 NZ NZ594193A patent/NZ594193A/xx not_active IP Right Cessation
- 2010-02-09 PE PE2011001445A patent/PE20120580A1/es not_active Application Discontinuation
- 2010-02-09 UA UAA201110844A patent/UA103791C2/uk unknown
- 2010-02-09 AP AP2011005849A patent/AP3437A/xx active
- 2010-02-09 US US13/148,659 patent/US20120149716A1/en not_active Abandoned
- 2010-02-09 BR BRPI1007500A patent/BRPI1007500A2/pt not_active IP Right Cessation
- 2010-02-09 CA CA2750123A patent/CA2750123A1/en not_active Abandoned
- 2010-02-09 PE PE2015000636A patent/PE20151143A1/es not_active Application Discontinuation
- 2010-02-09 EP EP14170043.5A patent/EP2818164A1/en not_active Withdrawn
-
2011
- 2011-07-19 IL IL214176A patent/IL214176A/en not_active IP Right Cessation
- 2011-07-29 CR CR20110411A patent/CR20110411A/es unknown
- 2011-08-09 NI NI201100154A patent/NI201100154A/es unknown
- 2011-08-21 EC EC2011011295A patent/ECSP11011295A/es unknown
- 2011-09-09 CO CO11116668A patent/CO6410289A2/es not_active Application Discontinuation
-
2015
- 2015-04-13 JP JP2015081559A patent/JP2015164928A/ja active Pending
- 2015-06-30 HK HK15106201.5A patent/HK1205681A1/xx unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001045702A1 (en) * | 1999-12-21 | 2001-06-28 | Celgene Corporation | SUBSTITUTED ACYLHYDROXAMIC ACIDS AND METHOD OF REDUCING TNFα LEVELS |
WO2003080049A1 (en) * | 2002-03-20 | 2003-10-02 | Celgene Corporation | (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
WO2004043378A2 (en) * | 2002-11-06 | 2004-05-27 | Celgene Corporation | Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases |
WO2007108750A1 (en) * | 2006-03-22 | 2007-09-27 | Astrazeneca Ab | Pyridopyrimidine derivatives and their use as pde4 inhibitors |
Non-Patent Citations (1)
Title |
---|
MARRIOTT J B ET AL: "CC-3052: a water-soluble analog of thalidomide and potent inhibitor of activation-induced TNF-alpha production.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 15 OCT 1998 LNKD- PUBMED:9780198, vol. 161, no. 8, 15 October 1998 (1998-10-15), pages 4236-4243 * |
Also Published As
Publication number | Publication date |
---|---|
JP2012517441A (ja) | 2012-08-02 |
SG173149A1 (en) | 2011-08-29 |
CA2750123A1 (en) | 2010-08-19 |
AP2011005849A0 (en) | 2011-08-31 |
IL214176A (en) | 2016-09-29 |
SG10201402158VA (en) | 2014-07-30 |
AU2010213936B2 (en) | 2014-07-31 |
CR20110411A (es) | 2012-01-06 |
EA201171035A1 (ru) | 2012-02-28 |
HK1205681A1 (en) | 2015-12-24 |
CO6410289A2 (es) | 2012-03-30 |
UA103791C2 (uk) | 2013-11-25 |
EP2395995A1 (en) | 2011-12-21 |
NZ594193A (en) | 2013-09-27 |
WO2010093588A1 (en) | 2010-08-19 |
IL214176A0 (en) | 2011-08-31 |
US20120149716A1 (en) | 2012-06-14 |
PE20120580A1 (es) | 2012-05-23 |
MX2011008132A (es) | 2011-09-06 |
JP2015164928A (ja) | 2015-09-17 |
KR20110116049A (ko) | 2011-10-24 |
CN102387798A (zh) | 2012-03-21 |
NI201100154A (es) | 2012-01-24 |
MY160002A (en) | 2017-02-15 |
PE20151143A1 (es) | 2015-08-07 |
ECSP11011295A (es) | 2011-09-30 |
BRPI1007500A2 (pt) | 2016-02-16 |
AU2010213936A1 (en) | 2011-08-11 |
EP2818164A1 (en) | 2014-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AP3437A (en) | Methods of using and compositions comprising pde4 modulations for treatment, prevention and management of tuberculosis | |
EP2614369A4 (en) | HEMMER OF HUMAN EZH2 AND METHOD FOR THEIR USE | |
HK1194071A1 (en) | Certain triazolopyrazines, compositions thereof and methods of use therefor | |
HK1162352A1 (en) | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof -3- | |
EP2640395A4 (en) | TREATMENT OF DISEASES ASSOCIATED WITH SEARCH AND PULSE CONTROL BY PDE7 INHIBITORS | |
EP2303193A4 (en) | DEVICES AND METHOD FOR TREATING CRANE AND OTHER JOINTS | |
IL217340A0 (en) | Devices and methods for tissue engineering | |
EP2262450A4 (en) | IMPLANTS AND METHODS OF USE | |
EP2293800A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF EARLIER DISEASES | |
EP2361089A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED FUNCTION OF -SYNUCLEINE | |
IL218663A0 (en) | Devices and methods for tissue engineering | |
ME01883B (me) | Deuterijumski derivati izoindolin-1,3-diona kao inhibitori pde4 i tnf-alfa | |
EP2326375A4 (en) | DEVICES AND METHOD FOR MINIMIZING AND TREATING HEIGHT-RELATED APPLICATIONS | |
EP2519290A4 (en) | DENTAL SELF-MIXING PROCEDURES, DEVICES AND COMPOSITIONS | |
EP2429584A4 (en) | TREATMENT PROCEDURE AND COMPOSITIONS | |
EP2164978A4 (en) | COMPOSITIONS AND METHODS FOR MODULATING ADAMTS13 ACTIVITY | |
EP2640391A4 (en) | PYRIDAZINE DERIVATIVES, COMPOSITIONS AND METHOD FOR TREATING COGNITIVE DISORDER | |
ZA201301936B (en) | Methods and compositions for treatment of diabetes and dyslipidemia | |
HK1193379A1 (en) | Remedial composition and treatment methods | |
EP2300495A4 (en) | SOLUTIONS FOR TISSUE MANIPULATION AND APPLICATION METHODS | |
EP2437771A4 (en) | COMPOSITIONS AND METHODS MODULATING MG29 FOR THE TREATMENT OF DIABETES | |
EP2300044A4 (en) | METHOD AND COMPOSITIONS FOR TREATING PAIN WITH OMEGA CONOTOXINES | |
HK1136303A1 (en) | Formulation and use of ergosta-7,22-dien-3-ol -722--3- | |
GB0808326D0 (en) | Compositions and methods for the treatment of fybromyalgia | |
IL209658A0 (en) | Compositions and methods for treatment of ear disorders |